AGA Data Trends 2025: IBD

Article Type
Article
Changed
Fri, 05/02/2025 - 09:38
Display Headline

The Role of Bedside Intestinal Ultrasound in IBD Management

Author(s)
Bincy Abraham, MD

Click here to view more from Gastroenterology Data Trends 2025.

References
  1. Chavannes M, Dolinger MT, Cohen-Mekelburg S, Abraham B. AGA Clinical Practice update on the Role of Intestinal Ultrasound in Inflammatory Bowel Disease: Commentary. Clin Gastroenterol Hepatol. 2024;22(9):1790-1795.e1. doi:10.1016/j.cgh.2024.04.039
  2. El-Nakeep S. The intestinal ultrasound role in inflammatory bowel disease in clinical practice and a critical appraisal of the current guidelines (mini-review). Egypt J Intern Med. 2024;36:51. doi:10.1186/s43162-024-00316-6
  3. Chavannes M, Hart L, Hayati Rezvan P, Dillman JR, Polk DB. Bedside Intestinal Ultrasound Predicts Disease Severity and the Disease Distribution of Pediatric Patients With Inflammatory Bowel Disease: A Pilot Cross-sectional Study. Inflamm Bowel Dis. 2024;30(3):402-409. doi:10.1093/ibd/izad083
  4. St-Pierre J, Delisle M, Kheirkhahrahimabadi H, et al; International Bowel Ultrasound Group. Bedside Intestinal Ultrasound Performed in an Inflammatory Bowel Disease Urgent Assessment Clinic Improves Clinical Decision-making and Resource Utilization. Crohns Colitis 360. 2023;5(4):otad050. doi:10.1093/crocol/otad050
  5. Jevdokimova N, Jevdokimov D, Teterina I, Pokrotnieks J,  Puķītis A, Mokricka V. Correlation of Intestinal Ultrasound Data With Laboratory Markers of Inflammation for Patients With Inflammatory Bowel Disease. Proc Latv Acad Sci, Sec B: Natural, Exact, and Applied Sci. 2024;section B;78(4):290-297. doi:10.2478/prolas-2024-0040
Author and Disclosure Information

Bincy Abraham, MD, MS 
Professor, Department of Internal Medicine and Gastroenterology; 
Director, Fondren IBD Program; 
Director, Gastroenterology Fellowship; 
Department of Internal Medicine and Gastroenterology, Houston Methodist Academic Gastroenterology Associates
Houston, Texas 

Bincy Abraham, MD, MS, has disclosed the following relevant financial relationships: Serve(d) as a consultant for: Abbvie; BMS; Janssen; Pfizer; Takeda; Celltrion; Lilly; Prometheus Serve(d) as a speaker or a member of a speakers bureau for: Abbvie; BMS; Janssen; Pfizer; Takeda; Lilly; Prometheus

Publications
GI and Hepatology News
Author(s)
Bincy Abraham, MD
Author(s)
Bincy Abraham, MD
Author and Disclosure Information

Bincy Abraham, MD, MS 
Professor, Department of Internal Medicine and Gastroenterology; 
Director, Fondren IBD Program; 
Director, Gastroenterology Fellowship; 
Department of Internal Medicine and Gastroenterology, Houston Methodist Academic Gastroenterology Associates
Houston, Texas 

Bincy Abraham, MD, MS, has disclosed the following relevant financial relationships: Serve(d) as a consultant for: Abbvie; BMS; Janssen; Pfizer; Takeda; Celltrion; Lilly; Prometheus Serve(d) as a speaker or a member of a speakers bureau for: Abbvie; BMS; Janssen; Pfizer; Takeda; Lilly; Prometheus

Author and Disclosure Information

Bincy Abraham, MD, MS 
Professor, Department of Internal Medicine and Gastroenterology; 
Director, Fondren IBD Program; 
Director, Gastroenterology Fellowship; 
Department of Internal Medicine and Gastroenterology, Houston Methodist Academic Gastroenterology Associates
Houston, Texas 

Bincy Abraham, MD, MS, has disclosed the following relevant financial relationships: Serve(d) as a consultant for: Abbvie; BMS; Janssen; Pfizer; Takeda; Celltrion; Lilly; Prometheus Serve(d) as a speaker or a member of a speakers bureau for: Abbvie; BMS; Janssen; Pfizer; Takeda; Lilly; Prometheus

Click here to view more from Gastroenterology Data Trends 2025.

Click here to view more from Gastroenterology Data Trends 2025.

References
  1. Chavannes M, Dolinger MT, Cohen-Mekelburg S, Abraham B. AGA Clinical Practice update on the Role of Intestinal Ultrasound in Inflammatory Bowel Disease: Commentary. Clin Gastroenterol Hepatol. 2024;22(9):1790-1795.e1. doi:10.1016/j.cgh.2024.04.039
  2. El-Nakeep S. The intestinal ultrasound role in inflammatory bowel disease in clinical practice and a critical appraisal of the current guidelines (mini-review). Egypt J Intern Med. 2024;36:51. doi:10.1186/s43162-024-00316-6
  3. Chavannes M, Hart L, Hayati Rezvan P, Dillman JR, Polk DB. Bedside Intestinal Ultrasound Predicts Disease Severity and the Disease Distribution of Pediatric Patients With Inflammatory Bowel Disease: A Pilot Cross-sectional Study. Inflamm Bowel Dis. 2024;30(3):402-409. doi:10.1093/ibd/izad083
  4. St-Pierre J, Delisle M, Kheirkhahrahimabadi H, et al; International Bowel Ultrasound Group. Bedside Intestinal Ultrasound Performed in an Inflammatory Bowel Disease Urgent Assessment Clinic Improves Clinical Decision-making and Resource Utilization. Crohns Colitis 360. 2023;5(4):otad050. doi:10.1093/crocol/otad050
  5. Jevdokimova N, Jevdokimov D, Teterina I, Pokrotnieks J,  Puķītis A, Mokricka V. Correlation of Intestinal Ultrasound Data With Laboratory Markers of Inflammation for Patients With Inflammatory Bowel Disease. Proc Latv Acad Sci, Sec B: Natural, Exact, and Applied Sci. 2024;section B;78(4):290-297. doi:10.2478/prolas-2024-0040
References
  1. Chavannes M, Dolinger MT, Cohen-Mekelburg S, Abraham B. AGA Clinical Practice update on the Role of Intestinal Ultrasound in Inflammatory Bowel Disease: Commentary. Clin Gastroenterol Hepatol. 2024;22(9):1790-1795.e1. doi:10.1016/j.cgh.2024.04.039
  2. El-Nakeep S. The intestinal ultrasound role in inflammatory bowel disease in clinical practice and a critical appraisal of the current guidelines (mini-review). Egypt J Intern Med. 2024;36:51. doi:10.1186/s43162-024-00316-6
  3. Chavannes M, Hart L, Hayati Rezvan P, Dillman JR, Polk DB. Bedside Intestinal Ultrasound Predicts Disease Severity and the Disease Distribution of Pediatric Patients With Inflammatory Bowel Disease: A Pilot Cross-sectional Study. Inflamm Bowel Dis. 2024;30(3):402-409. doi:10.1093/ibd/izad083
  4. St-Pierre J, Delisle M, Kheirkhahrahimabadi H, et al; International Bowel Ultrasound Group. Bedside Intestinal Ultrasound Performed in an Inflammatory Bowel Disease Urgent Assessment Clinic Improves Clinical Decision-making and Resource Utilization. Crohns Colitis 360. 2023;5(4):otad050. doi:10.1093/crocol/otad050
  5. Jevdokimova N, Jevdokimov D, Teterina I, Pokrotnieks J,  Puķītis A, Mokricka V. Correlation of Intestinal Ultrasound Data With Laboratory Markers of Inflammation for Patients With Inflammatory Bowel Disease. Proc Latv Acad Sci, Sec B: Natural, Exact, and Applied Sci. 2024;section B;78(4):290-297. doi:10.2478/prolas-2024-0040
Publications
GI and Hepatology News
Publications
GI and Hepatology News
Article Type
Article
Display Headline

The Role of Bedside Intestinal Ultrasound in IBD Management

Display Headline

The Role of Bedside Intestinal Ultrasound in IBD Management

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
SLIDESHOW
Gate On Date
Tue, 04/29/2025 - 12:41
Un-Gate On Date
Tue, 04/29/2025 - 12:41
Use ProPublica
CFC Schedule Remove Status
Tue, 04/29/2025 - 12:41
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Article Slideshow Optional Introduction

Patients with inflammatory bowel disease (IBD) need accessible, timely, and noninvasive monitoring strategies. Bedside intraabdominal ultrasound (IUS) is a beneficial tool for diagnosing and monitoring patients with IBD, including both Crohn's disease and ulcerative colitis.1,2 Integrating IUS can have a significant impact on decision-making and endoscopy use in a standardized care pathway for these patients, given that the benefits outweigh the risks and costs of other imaging modalities.

IUS is radiation free, and provides accurate point-of-care detection of bowel wall thickening and inflammation in individuals with IBD.3 This imaging is effective for monitoring treatment response and guiding early interventions and is suitable for special populations (e.g., pediatrics and patients who are pregnant or obese).1,2 IUS allows for medication adjustments without requiring urgent endoscopies or special preparations.1 The small and large intestine can be visually monitored for IBD activity with IUS, with occasional exception regarding the rectum because of its deep location; however, a transperineal or transrectal ultrasound approach may be needed to view the rectum and perianal areas.2,3

Further, in 2024, AGA reviewed and provided guidance on the use of IUS in IBD care,1 underscoring its growing importance and utility. IUS provides a noninvasive, cost-effective, and accurate method for IBD evaluation and monitoring.

Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Tue, 04/29/2025 - 12:41
Slide Media

Treatment Advances in Moderate to Severe Active Ulcerative Colitis

Article Type
Article
Changed
Tue, 03/29/2022 - 10:02
Author(s)
Bincy Abraham, MD

Treatment for moderate to severe active ulcerative colitis (UC) has evolved, and with more effective treatment comes higher standards for disease control. 

 

The initial goal is clinical response, followed by clinical remission, endoscopic remission, and — the ultimate goal — histologic remission.  

 

The majority of UC medications have been studied for clinical and endoscopic remission. Recent clinical trials, however, have evaluated the emerging targeted therapies ustekinumab and ozanimod for histologic remission and found positive results.  

 

Dr Bincy Abraham, director of the Fondren Inflammatory Bowel Disease Program at Houston Methodist in Houston, Texas, reports on UC treatment milestones and how emerging targeted therapies can help achieve these goals. 

 

She also discusses patient monitoring to ensure response to therapy as well as medication adjustments should response prove inadequate. 

--

Professor of Clinical Medicine, Department of Internal Medicine and Gastroenterology; Director, Fondren Inflammatory Bowel Disease Program, Underwood Center for Digestive Disorders, Houston Methodist, Houston, Texas 

 

Bincy Abraham, MD, has disclosed the following relevant financial relationships: 

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; BMS; Janssen; Pfizer; Takeda; Medtronic 

Serve(d) as a speaker or a member of a speakers bureau for: AbbVie; BMS; Janssen; Pfizer; Takeda 

Received research grant from: Takeda; BMS; Genentech 

Publications
GI and Hepatology News
Sections
Recap
Author(s)
Bincy Abraham, MD
Author(s)
Bincy Abraham, MD

Treatment for moderate to severe active ulcerative colitis (UC) has evolved, and with more effective treatment comes higher standards for disease control. 

 

The initial goal is clinical response, followed by clinical remission, endoscopic remission, and — the ultimate goal — histologic remission.  

 

The majority of UC medications have been studied for clinical and endoscopic remission. Recent clinical trials, however, have evaluated the emerging targeted therapies ustekinumab and ozanimod for histologic remission and found positive results.  

 

Dr Bincy Abraham, director of the Fondren Inflammatory Bowel Disease Program at Houston Methodist in Houston, Texas, reports on UC treatment milestones and how emerging targeted therapies can help achieve these goals. 

 

She also discusses patient monitoring to ensure response to therapy as well as medication adjustments should response prove inadequate. 

--

Professor of Clinical Medicine, Department of Internal Medicine and Gastroenterology; Director, Fondren Inflammatory Bowel Disease Program, Underwood Center for Digestive Disorders, Houston Methodist, Houston, Texas 

 

Bincy Abraham, MD, has disclosed the following relevant financial relationships: 

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; BMS; Janssen; Pfizer; Takeda; Medtronic 

Serve(d) as a speaker or a member of a speakers bureau for: AbbVie; BMS; Janssen; Pfizer; Takeda 

Received research grant from: Takeda; BMS; Genentech 

Treatment for moderate to severe active ulcerative colitis (UC) has evolved, and with more effective treatment comes higher standards for disease control. 

 

The initial goal is clinical response, followed by clinical remission, endoscopic remission, and — the ultimate goal — histologic remission.  

 

The majority of UC medications have been studied for clinical and endoscopic remission. Recent clinical trials, however, have evaluated the emerging targeted therapies ustekinumab and ozanimod for histologic remission and found positive results.  

 

Dr Bincy Abraham, director of the Fondren Inflammatory Bowel Disease Program at Houston Methodist in Houston, Texas, reports on UC treatment milestones and how emerging targeted therapies can help achieve these goals. 

 

She also discusses patient monitoring to ensure response to therapy as well as medication adjustments should response prove inadequate. 

--

Professor of Clinical Medicine, Department of Internal Medicine and Gastroenterology; Director, Fondren Inflammatory Bowel Disease Program, Underwood Center for Digestive Disorders, Houston Methodist, Houston, Texas 

 

Bincy Abraham, MD, has disclosed the following relevant financial relationships: 

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; BMS; Janssen; Pfizer; Takeda; Medtronic 

Serve(d) as a speaker or a member of a speakers bureau for: AbbVie; BMS; Janssen; Pfizer; Takeda 

Received research grant from: Takeda; BMS; Genentech 

Publications
GI and Hepatology News
Publications
GI and Hepatology News
Article Type
Article
Sections
Recap
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Fri, 03/04/2022 - 14:00
Un-Gate On Date
Fri, 03/04/2022 - 14:00
Use ProPublica
CFC Schedule Remove Status
Fri, 03/04/2022 - 14:00
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Conference Recap
video_before_title

Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Activity Salesforce Deliverable ID
327261.1
Activity ID
83098
Product Name
Research Capsule (ReCAP)
Product ID
80
Supporter Name /ID
Xeljanz [ 3700 ]
Subscribe to Bincy Abraham, MD